| Literature DB >> 25460310 |
Di Qu1, Jing Li2, Xiao-Hui Yang3, Zi-Dan Zhang4, Xiao-Xing Luo5, Ming-Kai Li6, Xia Li7.
Abstract
Five novel biscoumarins 1-5 were synthesized and characterized. In these compounds, two classical asymmetrical intramolecular O-H···O hydrogen bonds were used to stabilize the whole structures and the HB energies were performed with the density functional theory (DFT) [B3LYP/6-31G*] method. The five compounds were evaluated for their in vitro antibacterial activities against Staphylococcus aureus (S. aureus ATCC 29213), methicillin-resistant S. aureus (MRSA XJ 75302), vancomycin-intermediate S. aureus (Mu50 ATCC 700699), and USA 300 (Los Angeles County clone, LAC) by the means of minimum inhibitory concentration and time-kill curves.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25460310 PMCID: PMC6271470 DOI: 10.3390/molecules191219868
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structures of compounds 1–5.
Figure 2Crystal structures of compounds 1 and 5.
Figure 3Schematic representation of compounds 1–5.
Experimental and calculated parameters of the selected bond lengths and bond angles of compounds 1 and 5.
| Name Definition | Compound 1 | Compound 5 | ||||||
|---|---|---|---|---|---|---|---|---|
| X-ray | 6-31G* | 6-31+G** | 6-311G* | X-ray | 6-31G* | 6-31+G** | 6-311G* | |
| O3···O4 | 2.592 | 2.639 | 2.614 | 2.643 | 2.587 | 2.643 | 2.621 | 2.648 |
| O1···O6 | 2.697 | 2.704 | 2.695 | 2.711 | 2.709 | 2.698 | 2.686 | 2.706 |
| C19=O4 | 1.234 | 1.229 | 1.232 | 1.222 | 1.192 | 1.229 | 1.232 | 1.222 |
| C1=O1 | 1.235 | 1.233 | 1.236 | 1.226 | 1.214 | 1.233 | 1.236 | 1.226 |
| C1-O2 | 1.361 | 1.372 | 1.370 | 1.371 | 1.309 | 1.373 | 1.371 | 1.372 |
| C9-O2 | 1.355 | 1.367 | 1.369 | 1.366 | 1.324 | 1.368 | 1.369 | 1.366 |
| C19-O5 | 1.352 | 1.376 | 1.373 | 1.375 | 1.318 | 1.377 | 1.375 | 1.377 |
| C18-O5 | 1.354 | 1.367 | 1.368 | 1.365 | 1.389 | 1.367 | 1.368 | 1.365 |
| C10-C20 | 1.514 | 1.521 | 1.522 | 1.520 | 1.412 | 1.529 | 1.529 | 1.528 |
| C1-C2-C10 | 113.63 | 114.14 | 114.12 | 113.94 | 113.38 | 114.62 | 114.65 | 114.40 |
| C3-C2-C10 | 126.92 | 126.33 | 126.55 | 126.52 | 126.59 | 125.76 | 125.91 | 125.96 |
| C10-C11-C19 | 119.17 | 118.92 | 119.07 | 118.71 | 115.55 | 119.12 | 119.37 | 118.90 |
| C10-C11-C12 | 122.30 | 121.42 | 121.47 | 121.58 | 127.08 | 121.40 | 121.37 | 121.56 |
| C2-C10-C11 | 112.56 | 113.41 | 113.58 | 113.51 | 110.78 | 112.96 | 113.15 | 113.03 |
| C2-C10-C20 | 116.66 | 114.66 | 114.89 | 114.82 | 114.91 | 114.48 | 114.43 | 114.59 |
| C11-C10-C20 | 111.34 | 113.97 | 114.02 | 113.95 | 115.93 | 115.02 | 115.38 | 115.01 |
| C3-C2-C10-C11 | 84.78 | 83.91 | 83.52 | 84.56 | 88.12 | 87.60 | 87.46 | 88.20 |
| C2-C10-C11-C19 | 82.36 | 83.36 | 83.13 | 83.08 | 87.43 | 81.07 | 80.59 | 80.82 |
| C1-C2-C10-C20 | 136.87 | 134.30 | 133.69 | 134.30 | 134.62 | 135.07 | 134.21 | 135.02 |
| C19-C11-C10-C20 | 50.79 | 50.27 | 51.08 | 50.88 | 45.85 | 52.90 | 53.89 | 53.37 |
Total electronic energies (in Hartree) and HB energies (in kJ/mol) of hydrogen bonded conformers of compounds 1–5 calculated at B3LYP/6-31G* level of theory.
| System | Total Electronic Energies a | E(O6—H6···O1) | E(O3—H3···O4) | E(Total HB) |
|---|---|---|---|---|
| −1734.116678 | −125.4805215 | |||
| −1734.096324 | −53.439427 | |||
| −1734.089239 | −72.0410945 | |||
| −4305.229694 | −122.274786 | |||
| −4305.209554 | −52.87757 | |||
| −4305.203262 | −69.397216 | |||
| −4305.225972 | −123.529775 | |||
| −4305.206014 | −52.399729 | |||
| −4305.19888 | −71.130046 | |||
| −1773.408037 | −126.743387 | |||
| −1773.387526 | −53.8516305 | |||
| −1773.380274 | −72.8917565 | |||
| −1734.116974 | −116.0287215 | |||
| −1734.097714 | −50.56713 | |||
| −1734.092041 | −65.4615915 |
a: ZP corrected.
MIC of compounds 1–5 and antibiotics in Mueller-Hinton Broth Culture.
| Drug | MIC (ug/mL) | |||
|---|---|---|---|---|
| MRSA | Mu50 | LAC | ||
| Compound | 8 | 8 | 16 | 32 |
| Compound | 64 | 64 | 64 | 128 |
| Compound | 64 | 64 | 64 | 128 |
| Compound | 32 | 32 | 32 | 32 |
| Compound | >256 | >256 | >256 | >256 |
| Ceftazidime | 8 (S) | >256 (R) | 256 (R) | 64 (R) |
| Ceftriaxone | 2 (S) | >256 (R) | 256 (R) | 32 (R) |
| Gentamicin | 0.12 (S) | 64 (R) | 32 (R) | 0.25 (S) |
| Piperacillin | 2 (S) | >128 (R) | >128 (R) | 64 (R) |
S means drug susceptibility; R means drug resistance. Ceftazidime, ceftriaxone, gentamicin, and piperacillin as control antibiotics exert anti-bacterial effects on the drug-susceptible S. aureas strain (ATCC 29213). MRSA (XJ 75302) and Mu50 (ATCC 700699) are resistant to all of the control antibiotics, whereas LAC (USA 300) is susceptible to gentamicin but resistant to the other control antibiotics.
Figure 4Concentration-dependent inhibition of compound 1 on the growth of S. aureus ATCC 29213, MRSA XJ 75302, Mu50, and MRSA USA 300 LAC. The cells were cultured in liquid culture medium and treated with different concentrations of compound 1.
Crystal data, data collection and structure refinement.
| Parameter | Compound 1 | Compound 5 |
|---|---|---|
| Formula | C23H14O6S | C23H14O6S |
| 418.40 | 418.40 | |
| Temperature/K | 113(2) | 293(2) |
| Crystal system | Monoclinic | Monoclinic |
| Space group | ||
| 7.7250(8) | 7.7983(4) | |
| 8.9250(10) | 8.9785(5) | |
| 26.537(2) | 26.6473(19) | |
| α/° | 90 | 90 |
| β/° | 96.319(9) | 96.514(6) |
| γ/° | 90 | 90 |
| 1818.5(3) | 1853.72(19) | |
| 4 | 4 | |
| 1.528 | 3.009 | |
| μ(Mo Kα)/mm−1 | 1.951 | 1.711 |
| θ range/° | 3.35 to 72.59 | 2.40 to 25.00 |
| Reflections collected | 15733 | 6656 |
| No. unique data[ | 3541[0.0619] | 3261[0.0307] |
| No. data with | 3242 | 1892 |
| 0.0603 | 0.2049 | |
| ω | 0.1362 | 0.6273 |
| CCDC | 889260 | 1014707 |